uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Targeting EZH2 in Multiple Myeloma-Multifaceted Anti-Tumor Activity
Univ Florida, Hlth Canc Ctr, Div Hematol & Oncol, Dept Med, Gainesville, FL 32610 USA.
Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology.
Univ Florida, Hlth Canc Ctr, Div Hematol & Oncol, Dept Med, Gainesville, FL 32610 USA.
2018 (English)In: EPIGENOMES, ISSN 2075-4655, Vol. 2, no 3, article id 16Article, review/survey (Refereed) Published
Abstract [en]

The enhancer of zeste homolog 2 (EZH2) is the enzymatic subunit of the polycomb repressive complex 2 (PRC2) that exerts important functions during normal development as well as disease. PRC2 through EZH2 tri-methylates histone H3 lysine tail residue 27 (H3K27me3), a modification associated with repression of gene expression programs related to stem cell self-renewal, cell cycle, cell differentiation, and cellular transformation. EZH2 is deregulated and subjected to gain of function or loss of function mutations, and hence functions as an oncogene or tumor suppressor gene in a context-dependent manner. The development of highly selective inhibitors against the histone methyltransferase activity of EZH2 has also contributed to insight into the role of EZH2 and PRC2 in tumorigenesis, and their potential as therapeutic targets in cancer. EZH2 can function as an oncogene in multiple myeloma (MM) by repressing tumor suppressor genes that control apoptosis, cell cycle control and adhesion properties. Taken together these findings have raised the possibility that EZH2 inhibitors could be a useful therapeutic modality in MM alone or in combination with other targeted agents in MM. Therefore, we review the current knowledge on the regulation of EZH2 and its biological impact in MM, the anti-myeloma activity of EZH2 inhibitors and their potential as a targeted therapy in MM.

Place, publisher, year, edition, pages
MDPI, 2018. Vol. 2, no 3, article id 16
Keywords [en]
epigenetics, EZH2, multiple myeloma, epigenetic therapy
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:uu:diva-374874DOI: 10.3390/epigenomes2030016ISI: 000455137800004OAI: oai:DiVA.org:uu-374874DiVA, id: diva2:1284253
Funder
Swedish Research CouncilSwedish Cancer SocietyAvailable from: 2019-01-31 Created: 2019-01-31 Last updated: 2019-01-31Bibliographically approved

Open Access in DiVA

fulltext(1985 kB)12 downloads
File information
File name FULLTEXT01.pdfFile size 1985 kBChecksum SHA-512
249b029623ca1a594fc898236abed3ba106ab7444d74f4527ddaeacbc09d98766e43cc4d9e1e58efcd94751acf45bb653879b7fa1a0ccdd1ff7cae087244acd9
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Authority records BETA

Jernberg Wiklund, Helena

Search in DiVA

By author/editor
Jernberg Wiklund, Helena
By organisation
Science for Life Laboratory, SciLifeLabExperimental and Clinical Oncology
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 12 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 47 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf